CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Earnings & Estimates
NASDAQ:CYCC - US23254L8019 - Common Stock
7.49 USD
-0.06 (-0.79%)
7.51 USD
+0.02 (+0.27%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 420K | 43K -89.76% | 102K 137.21% | 102K | 82.194M 80,482.35% | 120.44M 46.53% | 145.3M 20.64% | 156.78M 7.90% | 162.76M 3.81% | ||
| EBITDA YoY % growth | -27.63M -20.66% | -25.422M 7.99% | -11.998M 52.80% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -27.66M -20.58% | -25.453M 7.98% | -12.004M 52.84% | -9.694M 19.24% | -9.897M -2.09% | 71.988M 827.37% | 110.02M 52.83% | 134.66M 22.40% | 145.92M 8.36% | 151.67M 3.94% | |
| Operating Margin | N/A | -6,060.24% | -27,916.28% | -9,504.00% | -9,703.00% | 87.58% | 91.35% | 92.68% | 93.07% | 93.19% | |
| EPS YoY % growth | -456.00 11.21% | -435.68 4.46% | N/A 99.54% | -1.20 39.49% | -1.14 5.08% | 3.74 427.68% | 5.60 49.59% | 5.40 -3.64% | 5.71 5.86% | 5.80 1.61% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.31 97.34% | -0.31 89.38% | -0.31 -3.45% |
| Revenue Q2Q % growth | 25.5K 537.50% | 25.5K 155.00% | 25.5K |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.411M 33.83% | -2.436M -11.89% | -2.46M -34.59% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -2.88 97.55% | -9.06 | 6.18 | 68.20% |
| Q2 2024 Q2Q % growth | -11.52 89.09% | -23.42 | 11.90 | 50.81% |
| Q1 2024 Q2Q % growth | -36.32 67.80% | -77.44 | 41.12 | 53.10% |
| Q4 2023 Q2Q % growth | -99.68 30.78% | -96.18 | -3.50 | -3.64% |
| Q3 2023 Q2Q % growth | -117.60 -16.67% | -88.94 | -28.66 | -32.22% |
| Q2 2023 Q2Q % growth | -105.60 4.35% | -123.22 | 17.62 | 14.30% |
| Q1 2023 Q2Q % growth | -112.80 -11.90% | -162.38 | 49.58 | 30.53% |
| Q4 2022 Q2Q % growth | -144.00 -11.11% | -118.12 | -25.88 | -21.91% |
| Q3 2022 Q2Q % growth | -100.80 22.22% | -137.90 | 37.10 | 26.91% |
| Q2 2022 Q2Q % growth | -110.40 17.86% | -153.06 | 42.66 | 27.87% |
| Q1 2022 Q2Q % growth | -100.80 16.00% | -167.50 | 66.70 | 39.82% |
| Q4 2021 Q2Q % growth | -129.60 59.70% | -159.94 | 30.34 | 18.97% |
| Q3 2021 Q2Q % growth | -129.60 -14.89% | -159.12 | 29.52 | 18.55% |
| Q2 2021 Q2Q % growth | -134.40 3.45% | -121.58 | -12.82 | -10.54% |
| Q1 2021 Q2Q % growth | -120.00 66.22% | -119.14 | -0.86 | -0.72% |
| Q4 2020 Q2Q % growth | -321.60 52.14% | -126.07 | -195.53 | -155.09% |
| Q3 2020 Q2Q % growth | -112.80 78.64% | -134.64 | 21.84 | 16.22% |
| Q2 2020 Q2Q % growth | -139.20 73.64% | -114.24 | -24.96 | -21.85% |
| Q1 2020 Q2Q % growth | -355.20 47.14% | -709.92 | 354.72 | 49.97% |
| Q4 2019 Q2Q % growth | -672.00 | -660.96 | -11.04 | -1.67% |
| Q3 2019 Q2Q % growth | -528.00 | -767.06 | 239.06 | 31.17% |
| Q2 2019 Q2Q % growth | -528.00 | -767.06 | 239.06 | 31.17% |
| Q1 2019 Q2Q % growth | -672.00 | -1,003.68 | 331.68 | 33.05% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 10K -37.50% | 5.1K | 4.9K | 96.08% |
| Q2 2024 Q2Q % growth | 4K -98.93% | 30.6K | -26.6K | -86.93% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | 0% | 0% | 0% | 0% |